Physician profile
Linda E Weber
NPI 1548201676
$3,000.81
in general payments reported to CMS, 2019-2025
18 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $495 · 2021: $844 · 2022: $264 · 2023: $271 · 2024: $412 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,002.93 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $659.16 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $214.66 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.23 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $184.39 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $118.62 | 2024 | |
| Axsome Therapeutics, INC. | $85.57 | 2025 | Auvelity |
| Allergan, INC. | $85.19 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.07 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.58 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.44 | 2023 | |
| Janssen Pharmaceuticals, INC | $47.13 | 2019-2020 | |
| Amarin Pharma, INC. | $47.01 | 2019-2021 | |
| Amgen INC. | $38.17 | 2024-2025 | Prolia, Evenity, Repatha |
| Pfizer INC. | $32.82 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.79 | 2022-2025 | Mounjaro, Zepbound |
| Ultragenyx Pharmaceutical INC. | $15.25 | 2019 | |
| Sumitomo Pharma America, INC. | $12.80 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.